MedTrace Logo

Cingularbio® Heart Valve Clincial Study

NCT02755220 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2022-04-28

No results posted yet for this study

Summary

This study aimed to evaluate the safety and effectiveness of Cingularbio® heart valve in Aortic Valve Replacement and Mitral Valve Replacement in Chinese population

Conditions

  • Diseases of Mitral and Aortic Valves

Interventions

DEVICE

Cingularbio® Aortic valve replacement

the patients will be replaced by Cingularbio heart valve

Sponsors & Collaborators

  • Shanghai Cingularbio Co. Ltd

    lead INDUSTRY

Principal Investigators

  • chunsheng wang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-12-31
Completion
2019-04-30

Countries

  • Belgium
  • China
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02755220 on ClinicalTrials.gov